JUBLINGREA · Concall Summary
JUBILANT INGREVIA LIMITED
During the earnings conference call for Q1 FY27, management reported a strong financial performance with revenue growth of 25% year-on-year and a 36% increase in EBITDA. The company highlighted resilience in demand across the chemical industry despite geopolitical uncertainties. Pharmaceuticals were noted as a key growth driver, with stable momentum in agrochemicals and healthy growth in the Nutrition and Personal Care markets. Management provided updates on their CDMO and Fine Chemicals pipeline, indicating a strong opportunity funnel with over 100 molecules. They also discussed operational achievements, including successful integration of Remidex Pharma and recognition for safety and workplace quality. Management set a goal for continued growth driven by Specialty Chemicals and Nutrition, alongside a recovery in acetyls, while maintaining guidance for EBITDA in the range of INR750 crore to INR800 crore for the year.
Management emphasized strong growth and operational achievements.
View source filing →Earlier concalls
- 2026-07-22 — Jubilant Ingrevia Limited reported strong financial results for the quarter ended June 30, 2026, with revenue increasing…
- 2026-05-29 — Management reported a strong performance for Q4 and FY '26, highlighting the highest quarterly revenue and EBITDA in 14 …
- 2026-05-26 — Jubilant Ingrevia Limited reported its financial results for Q4 and FY26, highlighting a 12% year-on-year revenue growth…
See JUBLINGREA's full Research Pro page — annual report summary, insider trades, promoter pledge trend, options positioning and Ask-RedixFi AI.
Sign up free